FDA Requires GLP-1 Drug Labels To Warn Of Potential Risk Of Permanent Vision Loss
SILVER SPRING, Md. — Manufacturers of glucagon-like peptide-1 receptor agonist XE "glucagon-like peptide-I receptor agonist" (GLP-1 RA) medications must add labeling warnings about a potential increased risk of non-arteritic anterior ischemic...To view the full article, register now.
Already a subscriber? Click here to view full article